<img src="https://ml.globenewswire.com/Resource/Download/079b6db5-ce81-4a81-9cde-d97f86c569ae?size=2" nborder="0" align="left" hspace="5" vspace="5" title="logo-banner-small.png" alt="Relay Therapeutics, Inc."/>CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ZYWCIWUEtghZi294uIlvtxu8YmzeO9PqOc04XDSnyN-zpngpEqv1MPjHripI7O5OhD4dqoxN1PSGe2FyjmqrRbIFAklYr-msGCTfYyJlMaY=" rel="nofollow" target="_blank" title="Relay Therapeutics, Inc.">Relay Therapeutics, Inc.</a> (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: <ul type="disc"><li>2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ET</li><li>Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET</li></ul> The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News &amp; Events section through the following link: <a href="https://www.globenewswire.com/Tracker?data=H48gVUHeYeGKImSBuyFJacFMnzaquBcPQhtDbF5X5knYBVgj6R2h_sw0V6__F2sJomGtRpmJ-LUb1r4GcbEAPLbSAkSgOydllY8BOnIQksu33sxIxg6_3A3cGW350aztTdoz8vkz699xz_sezEqx-nMTRFfSDi0sAvCOGSPP2XaUgLV6zS03LsnisSPJi3uI" rel="nofollow" target="_blank" title="">https://ir.relaytx.com/news-events/events-presentations</a>. An archived replay of the webcast will be available for up to 30 days following the event. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=P0uCMRHDO7m6eD90UFeFdCUf-MhhzLHZntf99Gg2inotF0vciEwS85q0wsFBKk9MrG68EsFejs_kDZrCt84JigNdg2vVZqiPaK2i7x3D6FA=" rel="nofollow" target="_blank" title="www.relaytx.com">www.relaytx.com</a> or <a href="https://www.globenewswire.com/Tracker?data=PuiRBPzxvkzypm7L_WC8R4frO4Q-OprVbWvFbB_-eh98yzLSmOMeJ-9pfuc3MEXkBz35el0b74kJ_W9cyScfG4FYN5m8g2GtMYB5_X3oHzI8jOe31Adfeo8z77s-zBdRTnlm_dLwXYsm7tECNA0tPvqMS9WJI63GLAmObu9JGWIesiGe7fYAjEtpyX2WAH9A_lBxiJlm9MRPCYVva3Ugcg==" rel="nofollow" target="_blank" title="follow us on LinkedIn">follow us on LinkedIn</a>. Contact: Mitch Maisel <a href="https://www.globenewswire.com/Tracker?data=lbXjkR5I9P4gKtTb-zn9k567iUC9UmWpJitQNriVl7Fc6vuzDZhSNKiGdXPHtpZc7a0gCVKfHPWwGzrR8FP9wGdkBarX39zwXT0ayVXrTMw=" rel="nofollow" target="_blank" title="mmaisel@relaytx.com">mmaisel@relaytx.com</a> Media: Dan Budwick 1AB 973-271-6085 <a href="https://www.globenewswire.com/Tracker?data=OUOMfhWdEi8Kuq7Z2mIPO7LB0xNISVJpkAcxe_w3RlXl25RKzEdLub5a4IBn0y4rwOmgPINePC29mhko-351z3VLXXQW3dnbsW_HdchTh0c=" rel="nofollow" target="_blank" title="dan@1abmedia.com">dan@1abmedia.com</a> <img alt="" src='https://ml.globenewswire.com/media/MDMwOTg3NGMtZWVmMC00ZTliLWIwOGEtZjNjNWJjYzA2NTAyLTEyMTEzMzgtMjAyNi0wNS0yNy1lbg==/tiny/Relay-Therapeutics-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn